Connection
David Camidge to Histone Deacetylase Inhibitors
This is a "connection" page, showing publications David Camidge has written about Histone Deacetylase Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.086 |
|
|
|
-
Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs. 2013 Feb; 31(1):115-25.
Score: 0.086